{
    "id": 29107,
    "fullName": "PRLR positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PRLR positive indicates the presence of the PRLR gene, mRNA, and or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5618,
        "geneSymbol": "PRLR",
        "terms": [
            "PRLR",
            "HPRL",
            "hPRLrI",
            "MFAB",
            "RI-PRLR"
        ]
    },
    "variant": "positive",
    "createDate": "12/10/2018",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15419,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, LFA102 treatment of patients (n=73) with PRLR-positive metastatic breast cancer or metastatic castration-resistant prostate cancer, did not result in clinical efficacy at any of five tested doses (PMID: 27091421, NCT01338831).",
            "molecularProfile": {
                "id": 31028,
                "profileName": "PRLR positive"
            },
            "therapy": {
                "id": 7615,
                "therapyName": "LFA102",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13205,
                    "pubMedId": 27091421,
                    "title": "Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27091421"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15418,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, LFA102 treatment of patients (n=73) with PRLR-positive metastatic breast cancer or metastatic castration-resistant prostate cancer, did not result in clinical efficacy at any of five tested doses (PMID: 27091421, NCT01338831).",
            "molecularProfile": {
                "id": 31028,
                "profileName": "PRLR positive"
            },
            "therapy": {
                "id": 7615,
                "therapyName": "LFA102",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13205,
                    "pubMedId": 27091421,
                    "title": "Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27091421"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31028,
            "profileName": "PRLR positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}